CERO Therapeutics Holdings, Inc. announced on April 10, 2025, the allowance of two patent applications by the U.S. Patent and Trademark Office (USPTO), significantly expanding its intellectual property portfolio. Patent Application No. 17/040,472, titled 'CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,' was allowed on March 13, 2025.
This patent provides coverage for composition of matter and methods of use for the company’s lead compound, CER-1236, encompassing the combination of a phosphatidylserine-targeting CD4+ CER-T cell with a CD8+ CAR-T cell or a CD8+ recombinant TCR-T cell, and their use to treat cancer. Additionally, USPTO allowed Patent Application No. 17/040,317, titled 'CHIMERIC TIM4 RECEPTORS AND USES THEREOF,' on March 24, 2025, covering design aspects of CER-1236.
With these additional allowances, CERO’s intellectual property portfolio now includes 17 total issued patents and allowed patent applications internationally across nine patent families, with protection extending out to 2039 in the United States. CEO Chris Ehrlich stated that these allowances are paramount to CERO’s market success, demonstrating the novelty of its design and approach in cancer treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.